瑞士罗氏的万赛维哪里有卖？

(Valganciclovir Hydrochloride Tablets) is a prodrug derivative of ganciclovir, developed and produced by Roche. In May 2001, the US FDA approved valganciclovir for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Vancevi is the first oral drug approved for this disease. The company has launched the drug in domestic and overseas markets. Currently, patients can purchase Vancevi at domestic hospitals. In China, the price of Vancevir can be said to be very expensive. A box of it is priced at about $17,000, and the drug specification is 450mg*60 tablets.

In foreign countries, the Vancevi sold in Türkiye is much cheaper in comparison. According to Medical Companion Travel, a box of the Turkish version of Vancevi is priced at about $3,000, and the drug specifications are also 450mg*60 tablets/box. Domestic patients who need this version of medicine can either go abroad to purchase it in person or obtain their specific drug purchase channels through medical companion travel.

The efficacy of induction therapy with Vancevac is similar to that of intravenous ganciclovir Cytovene IV and is expected to replace it. Roche said that Cytovene IV is currently the leading drug for the treatment of CMV retinitis. Other products approved for this indication in the United States are AstraZeneca's Foscavir (foscarnet sodium) and Gilead's Vistide (cidofovir).

  Roche is a world-renowned pharmaceutical company and the world's largest biotechnology company. It has a very broad business scope and provides a variety of innovative testing products and services to the world. Among them, Valganciclovir Hydrochloride Tablets (Valganciclovir Hydrochloride Tablets) produced by Roche of Switzerland received a lot of attention once it was launched, and has provided certain help for the treatment of many patients.

Recommended hot articles: /newsDetail/90655.html